Harrow, Inc. (NASDAQ: HROW), a U.S.-based provider of ophthalmic disease management solutions, announced on Friday that it ...

Harrow plans to submit a New Drug Application (“NDA”) to the FDA in 2027, with a potential U.S. commercial launch in 2028.

The acquisition will include Melt’s lead investigational therapy, MELT-300, designed to provide rapid, predictable sedation ...

Harrow (NASDAQ:HROW) to acquire Melt Pharmaceuticals, a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, ...

Netherlands: Midazolam sedation can noticeably restrict the natural adaptability of breathing, while s-ketamine largely ...

A 2024 Associated Press investigation into in-custody deaths examined 94 cases nationally involving forced sedation between 2012 and 2021 ... knelt down and injected him in the buttocks with midazolam ...

Objective: To identify and study the existing literature on the efficacy and safety of midazolam compared to inhalation of nitrous oxide in children undergoing dental treatment. Material and Methods: ...

Midazolam and fentanyl combination therapy may provide more comfort, fewer adverse events, and a shorter recovery time than midazolam and meperidine. Conscious sedation with midazolam and an opioid is ...

“It’s so fun to be a fan of the zodiac killer in pop star form,” a Swiftie named Lacey wrote on X a few hours before the official announcement of the new album arrived today at 12:12 a.m. EST. “The ...

Scientists have shown the efficacy of a new non-opioid oral painkiller known as ADRIANA, the world's first selective α2B-adrenoceptor antagonist – a receptor subtype not previously targeted for ...